![YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge | npj Vaccines YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge | npj Vaccines](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41541-023-00699-7/MediaObjects/41541_2023_699_Fig1_HTML.png)
YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge | npj Vaccines
![Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41541-022-00564-z/MediaObjects/41541_2022_564_Fig1_HTML.png)
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines
![Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades | Nature Communications Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-33112-3/MediaObjects/41467_2022_33112_Fig1_HTML.png)
Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades | Nature Communications
![Phylodynamic assessment of intervention strategies for the West African Ebola virus outbreak | Nature Communications Phylodynamic assessment of intervention strategies for the West African Ebola virus outbreak | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-018-03763-2/MediaObjects/41467_2018_3763_Fig1_HTML.jpg)
Phylodynamic assessment of intervention strategies for the West African Ebola virus outbreak | Nature Communications
![Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41541-023-00767-y/MediaObjects/41541_2023_767_Fig1_HTML.png)
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola | npj Vaccines
![Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020 | Scientific Reports Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020 | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-97667-9/MediaObjects/41598_2021_97667_Fig1_HTML.png)
Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020 | Scientific Reports
![Profile and reintegration experience of Ebola survivors in Guinea: a cross‐sectional study - Delamou - 2017 - Tropical Medicine & International Health - Wiley Online Library Profile and reintegration experience of Ebola survivors in Guinea: a cross‐sectional study - Delamou - 2017 - Tropical Medicine & International Health - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/07d41a3f-0496-426f-8464-3d97ddacf5c5/tmi.2017.22.issue-3.cover.jpg)
Profile and reintegration experience of Ebola survivors in Guinea: a cross‐sectional study - Delamou - 2017 - Tropical Medicine & International Health - Wiley Online Library
![Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/4eb8a236-ded3-4c80-b01b-23436bc85d78/gr1.jpg)